

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED

(Company Registration No. 91120000103100784F)

(Incorporated in People's Republic of China)

UPDATE ON CHANGE OF COMPANY NAME

- **CHANGE OF STOCK SHORT NAME FOR TRADING OF THE A-SHARES OF THE COMPANY**
 - **CHANGE OF TRADING COUNTER NAME FOR TRADING OF THE S-SHARES OF THE COMPANY**
-

The board of directors (the “Board”) and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board refers to the annexure to the notice of the annual general meeting of the Company for the financial year ended 31 December 2021 (“FY2021”) (the “2022 AGM”) dated 22 April 2022 relating to the proposed change of the Chinese name of the Company from “天津中新药业集团股份有限公司” to “津药达仁堂集团股份有限公司”, and the proposed change of the English name of the Company from “Tianjin Zhong Xin Pharmaceutical Group Corporation Limited” to “Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited” (the “**Proposed Change of Company Name**”), and consequential amendments to the Articles of Association of the Company in relation to the Proposed Change of Company Name and the application for changes in the industrial and commercial registration (as set out on pages 194 to 206 of the Company’s annual report for FY2021) (the “**Annexure**”).

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the Annexure.

The Company had on 22 April 2022 duly convened its 2nd board meeting for the financial year ending 31 December 2022, at which the Board considered and approved the Proposed Change of Company Name. On 16 May 2022, the Company duly convened its 2022 AGM and the Shareholders had at the 2022 AGM considered and approved, amongst others, the Proposed Change of Company Name. Please refer to the Annexure and the announcement dated 16 May 2022 made by the Company in relation to the poll results of the 2022 AGM held on 16 May 2022 for further details.

Further to the 2022 AGM where the resolution relating to the Proposed Change of Company Name was duly passed, in accordance with the applicable laws and regulations and the Articles of Association of the Company, upon application by the Company to the Tianjin Administration for Market Regulation (天津市市场监督管理委员会) (the “**TAMR**”) to update the industrial and commercial registration details pertaining to the Company which has been completed on 18 May 2022, the TAMR has issued a new business license (营业执照) to the Company (the “**New Business License**”) to confirm that the Chinese name of the Company is now “津药达仁堂集团股份有限公司”. As stated in the Annexure, there is no requirement for the registration of the English name of the Company with any competent authority in the PRC. Accordingly, the Proposed Change of Company Name is effective from **18 May 2022**. Please refer to the announcement

made by the Company on 19 May 2022 for further details on the New Business License. In view that the Chinese name of the Company has been changed to “津药达仁堂集团股份有限公司”, upon application by the Company and confirmation by the Shanghai Stock Exchange (the “**SSE**”), the stock short name for trading of the A-Shares on the SSE will be changed from “中新药业” to “达仁堂” with effect from **30 May 2022**. The stock code of the A-Shares will remain unchanged as “600329”.

The Company will be arranging with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) to change its trading counter name for trading of the S-Shares on the SGX-ST and in relation thereto, further announcement(s) will be made by the Company in due course.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
19 May 2022